MedTrace Logo

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

NCT00067626 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-10-15

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of Chromium on glucose tolerance and endothelial function in people at risk for type II diabetes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Chromium

500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Yale University

    collaborator OTHER

  • Griffin Hospital

    lead OTHER

Principal Investigators

  • David L Katz, MD, MPH · Yale University/Yale-Griffin Prevention Research Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00067626 on ClinicalTrials.gov